IGHV1-8: A Potential Drug Target and Biomarker (G28472)

Target Name: IGHV1-8

NCBI ID: G28472

IGHV1-8

Other Name(s): immunoglobulin heavy variable 1-8 | IGHV18 | Immunoglobulin heavy variable 1-8

IGHV1-8: A Potential Drug Target and Biomarker

IGHV1-8, also known as immunoglobulin heavy variable 1-8, is a protein that is found in the bloodstream. It is a type of antibody that is made by the immune system to help fight off infections and other harmful substances that may enter the body. IGHV1-8 is one of the proteins that is made up of five different subunits.

One of the main functions of IGHV1-8 is to help regulate the immune response. It is part of a system of proteins that work together to keep the immune system in check, so that it does not become too active and cause unnecessary reactions. This helps to keep the body safe from harmful substances and diseases.

IGHV1-8 is also a potential drug target. Researchers are studying it to see if it can be used to treat certain diseases, such as diabetes and cancer. They are also looking at it as a potential biomarker, which could be used to diagnose and monitor certain diseases.

One way that researchers are studying IGHV1-8 is to use it as a target for drugs. They are trying to develop drugs that can interfere with the function of IGHV1-8 in order to treat certain diseases. This is done by using techniques such as genetic engineering and bioremediation.

Another way that researchers are studying IGHV1-8 is to use it as a biomarker. IGHV1-8 is a protein that is found in the bloodstream, so it can be used as a measure of the level of certain proteins in the body. This can be useful for diagnosing and monitoring certain diseases.

IGHV1-8 is also of interest to researchers because of its unique structure. IGHV1-8 is made up of five different subunits, which gives it a unique shape. This shape may be important for its function in the immune system. Researchers are studying the structure of IGHV1-8 to see if it has any specific features that make it unique and important.

In conclusion, IGHV1-8 is a protein that is found in the bloodstream. It is part of a system of proteins that work together to keep the immune system in check and help regulate the immune response. IGHV1-8 is also a potential drug target and biomarker, and researchers are studying it to see if it has any potential for treating certain diseases.

Protein Name: Immunoglobulin Heavy Variable 1-8

Functions: V region of the variable domain of immunoglobulin heavy chains that participates in the antigen recognition (PubMed:24600447). Immunoglobulins, also known as antibodies, are membrane-bound or secreted glycoproteins produced by B lymphocytes. In the recognition phase of humoral immunity, the membrane-bound immunoglobulins serve as receptors which, upon binding of a specific antigen, trigger the clonal expansion and differentiation of B lymphocytes into immunoglobulins-secreting plasma cells. Secreted immunoglobulins mediate the effector phase of humoral immunity, which results in the elimination of bound antigens (PubMed:22158414, PubMed:20176268). The antigen binding site is formed by the variable domain of one heavy chain, together with that of its associated light chain. Thus, each immunoglobulin has two antigen binding sites with remarkable affinity for a particular antigen. The variable domains are assembled by a process called V-(D)-J rearrangement and can then be subjected to somatic hypermutations which, after exposure to antigen and selection, allow affinity maturation for a particular antigen (PubMed:20176268, PubMed:17576170)

The "IGHV1-8 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about IGHV1-8 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets